Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 14/20 | 0.61 |
| ▸ | DRD2 | P14416 | 11/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7411558 | 1.00 | DRD3 (0.61) | DRD3DRD2HTR1A | |
| SCHEMBL7403568 | 0.81 | DRD3 (0.67) | DRD3DRD2HTR1A | |
| SCHEMBL7403573 | 0.81 | DRD3 (0.67) | DRD3DRD2HTR1A | |
| SCHEMBL7408334 | 0.77 | DRD3 (0.61) | DRD3DRD2HTR1A | |
| SCHEMBL7408331 | 0.77 | DRD3 (0.61) | DRD3DRD2HTR1A | |
| SCHEMBL7405845 | 0.75 | DRD3 (0.54) | DRD3DRD2HTR1A | |
| SCHEMBL7405840 | 0.75 | DRD3 (0.54) | DRD3DRD2HTR1A | |
| SCHEMBL8681931 | 0.73 | DRD3 (0.76) | DRD3DRD2HTR1A | |
| SCHEMBL8683984 | 0.73 | DRD3 (0.68) | DRD3DRD2 | |
| SCHEMBL7503050 | 0.72 | DRD3 (0.60) | DRD3DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6084130-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0923542-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1997045403-A1 | ARYL SUBSTITUTED CYCLIC AMINES AS SELECTIVE DOPAMINE D3 LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |